Expression of ZNF385B in cancer - Summary

GENERAL INFORMATIONⁱ General description of the gene and the encoded protein(s) using information from HGNC and Ensembl, as well as predictions made by the Human Protein Atlas project.
Gene nameⁱ Official gene symbol, which is typically a short form of the gene name, according to HGNC.	ZNF385B
Gene descriptionⁱ Full gene name according to HGNC.	Zinc finger protein 385B
Predicted locationⁱ All transcripts of all genes have been analyzed regarding the location(s) of corresponding protein based on prediction methods for signal peptides and transmembrane regions. Genes with at least one transcript predicted to encode a secreted protein, according to prediction methods or to UniProt location data, have been further annotated and classified with the aim to determine if the corresponding protein(s) are secreted or actually retained in intracellular locations or membrane-attached. Remaining genes, with no transcript predicted to encode a secreted protein, will be assigned the prediction-based location(s). The annotated location overrules the predicted location, so that a gene encoding a predicted secreted protein that has been annotated as intracellular will have intracellular as the final location. Read more	Intracellular
Number of transcriptsⁱ Number of protein-coding transcripts from the gene as defined by Ensembl.	8

HUMAN PROTEIN ATLAS INFORMATIONⁱ

RNA categoryⁱ

Consensus (human tissue):	Tissue enhanced (retina) Detected in many
HPA (cell line):	Cell line enhanced (Daudi, HAP1, U-698) Detected in some
TCGA (cancer tissue):	Cancer enhanced (prostate cancer) Detected in many

Protein evidenceⁱ

Evidence at protein level

IMMUNOHISTOCHEMISTRY DATA RELIABILITY

Reliability score -
normal tissuesⁱ

Pending cancer tissue analysis.

PROGNOSTIC SUMMARYⁱ

Prognostic marker in renal cancer (favorable) and breast cancer (favorable)

Show all

RNA EXPRESSION OVERVIEWⁱ RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA datasetⁱ RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from. Read more RNA cancer category: Cancer enhanced (prostate cancer)

PROTEIN EXPRESSIONⁱ

Pending cancer tissue analysis.